GMAB: Late-stage pipeline advances and strong financials set up multiple key data readouts in Q4
Significant pipeline progress includes nine revenue-generating medicines, six new phase III trials, and strong financial growth. Petosemtamab and EPKINLY are advancing in late-stage trials, with multiple data readouts expected in Q4. Rina-S and CRC programs show high efficacy and broad applicabilit…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.